Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease

Pediatric Blood and Cancer

Volumn 56, Issue 1, 2011, Pages 45-49

  Pai, Vinita ^a,b   Porter, Kyle ^a   Ranalli, Mark ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Acute graft versus host disease; Chemotherapy induced diarrhea; Octreotide; Pediatric oncology patients; Treatment

Indexed keywords

CYTARABINE; ETOPOSIDE; NARCOTIC ANALGESIC AGENT; OCTREOTIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADVERSE DRUG REACTION; ARTICLE; CHEMOTHERAPY INDUCED DIARRHEA; CHILD; CHILDHOOD CANCER; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DIARRHEA; DRUG EVALUATION; DRUG TOXICITY; FEMALE; GASTROINTESTINAL AGENTS; GRAFT VS HOST DISEASE; HUMANS; MALE; OCTREOTIDE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78649644403     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22838     Document Type: Article

References (50)

1. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003, Publish Date: August 9, 2006.
2. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-715.
3. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-1311.
4. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-1135.
5. Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13: 222-226.
6. Camera A, Andretta C, Villa MR, et al. Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol J 2003; 4: 346-350.
7. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003; 21: 3844-3852.
8. Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006; 106: 703-707.
9. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: A SFOP and SFGM study. Eur J Cancer 1997; 33: 2368-2375.
10. Diaz MA, Vicent MG, Madero L. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157-1159.
11. Barker CC, Anderson RA, Sauve RS, et al. GI complications in pediatric patients post-BMT. Bone Marrow Transplant 2005; 36: 51-58.
12. Milles SS, Muggia AL, Spiro HM. Colonic histologic changes induced by 5-fluorouracil. Gastroenterology 1962; 43: 391-399.
13. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725.
14. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-3757.
15. Blijlevens NMA, Donnelly JP, DePauw BE. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haemotopoietic stem cell transplant. Bone Marrow Transplant 2005; 35: 707-711.
16. Ball LM, Egeler RM. Acute GVHD: Pathogenesis and classification. Bone Marrow Tranplant 2008; 41: S58-S64.
17. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
18. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft versus-host disease: Rational for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
19. Ferrara JL, Cooke KR, Teshima T. Pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181-187.
20. Chang RJ, Lee SH. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line. J Immunol 1986; 137: 2853-2856.
21. O'Dorisio T, Redfern JS. Somatostatin and somatostatin-like peptides: Clinical research and clinical implications. In: Mazzaferri YB, editor. Advances in endocrinology and metabolism. Chicago: Mosby Year Book; 1990. pp. 175-230.
22. Gyr KE, Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Metabolism 1992; 41: 17-21.
23. Creutzfeldt W, Lembcke B, Folsch UR, et al. Effect of somatostatin analogue (SMS201-995, Sandostatin) on pancreatic secretion in humans. Am J Med 1987; 82: 49-54.
24. Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989; 8: 255-272.
25. Dueno MI, Bai JC, Santangelo WC, et al. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Digestive Dis Sci 1987; 32: 1092-1096.
26. Fuessl HS, Carolan G, Williams G, et al. Effect of long acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-Tin colloid and mouth-to-cecum transit time in man. Digestion 1987; 36: 101-107.
27. Roberts WG, Fedorak RN, Chang EB. In vitro effects of long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum. Gastroenterology 1988; 94: 1343-1350.
28. Kutz K, Neusch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21: 65-72.
29. Novartis. Sandostatin (octreotide acetate) package insert, East Hanover, NJ September 2005.
30. Benson AB, Jr., Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment induced diarrhea. J Clin Oncol 2004; 22: 2918-2926.
31. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4: 443-445.
32. Barbounis V, Koumakis G, Vassilomanolakis M, et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001; 9: 258-260.
33. Goumas P, Naxakis S, Christopoulou A, et al. Octreotide acetate in the treatment of fluorouracil induced diarrhea. Oncologist 1998; 3: 50-53.
34. Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: Octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40: 1464-1473.
35. Dranitsaris G, Maroun J, Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 2005; 19: 83-87.
36. Rotherberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
37. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
38. Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on Chemotherapy-Induced diarrhea. Current Oncol 2007; 14: 13-20.
39. Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus Loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial. J Clin Oncol 1993; 11: 148-151.
40. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al. Bowel rest, intravenous hydration, and continuous high dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993; 72: 1543-1546.
41. Cascinu S, Fedeli A, Fedeli SL, et al. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28: 482-483.
42. Ginopoulos P, Papagiannis T, Safridi C, et al. Octreotide treatment of chemotherapy-induced diarrhoea. Eur J Cancer 1996; 32A: 182-183.
43. Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001; 12: 227-229.
44. Crouch MA, Restino MS, Cruz JM, et al. Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmacother 1996; 30: 331-336.
45. Wasserman E, Hidalgo M, Hornedo J, et al. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: Dose finding study and evaluation of efficacy. Bone Marrow Transplant 1997; 20: 711-714.
46. Goumas P, Naxakis S, Christopoulou A, et al. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998; 3: 50-53.
47. Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350-3354.
48. Pidala J, Kim J, Field T, et al. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 1116-1121.
49. Rao K, Rao A, Karlsson H, et al. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009; 31: 456-461.
50. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586.